Skip to main content
Equibles
IONS logo

IONS · Ionis Pharmaceuticals Inc

Track IONS — free

Use IONS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$52.29 -5.84 (-10.05%) At close · Sep 4
Russell 1000 member Rebalance outlook locked
Market Cap
$9.65B
Shares
166.18M

IONS metrics

73 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$58.13
Market cap
$9.65B

Price action

19 metrics
Price change (1W)
-6.9%
Price change (30D)
+6.7%
Price change (3M)
-22.6%
Price change (6M)
-22.7%
Price change (YTD)
-26.5%
Price change (1Y)
-3.9%
Trailing year
Price change (5Y)
+47.1%
52-week high
$86.50
52-week low
$51.77
Change from 52-week high
-32.8%
Change from 52-week low
+12.3%
Annualized volatility
40.3%
Beta
0.4
RSI (14D)
44.9
Price vs SMA 50
-5.7%
Price vs SMA 200
-20.9%
Avg volume (3M)
2.97M
Relative volume
1.5
Average dollar volume
$187.00M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
166.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
11.0×
reciprocal yield 9.1%
P / book
21.9
reciprocal yield 4.6%
FCF yield
-5.8%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.9%

Historical valuation

8 metrics
P / E historical average (3Y)
60.3×
reciprocal yield 1.7%
P / E historical average (5Y)
60.3×
reciprocal yield 1.7%
EV / revenue historical average (3Y)
8.1×
reciprocal yield 12.3%
EV / revenue historical average (5Y)
8.1×
reciprocal yield 12.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
98.2%
Operating margin
-68.0%
Trailing 12 months
Net margin
-64.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$594.36M
Net income (TTM)
−$565.17M
Trailing 12 months
Diluted EPS (TTM)
$-3.46
FCF margin
-64.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.95

Growth

11 metrics
Revenue growth YoY
-40.7%
Year over year
Net income growth YoY
-192.8%
Revenue (TTM)
$874.09M
Trailing 12 months
EPS growth YoY
-198.6%
Shares change YoY
-9.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+17.1%
Revenue CAGR (5Y)
+5.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-128.5%
Return on assets
-18.9%
Debt / equity
—
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$560.84M
Quick ratio
7.7
Interest coverage
-31.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$350.06M
Total assets
$2.99B
Total debt
$1.76B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$496.43M
Capital expenditures (TTM)
$64.41M
R&D (TTM)
$173.70M
SG&A (TTM)
$527.75M
Stock compensation (TTM)
$163.34M
R&D / revenue
—
Stock compensation / revenue
18.7%

Ownership (13F)

3 metrics
13F filers
521
13F filer change QoQ
+21
Institutional ownership
112.5%

Short interest

3 metrics
Short interest
12.6%
Latest settlement · 9.6 days to cover
Days to cover
9.6d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$18.01M
Insider-sentiment score
83 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 874015 CUSIP 462222100 13F (30d) 370 filings 356 filers Visit website Investor relations